NCT05517811 Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
| NCT ID | NCT05517811 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Liver Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2022-06-26 |
| Primary Completion | 2028-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2022-06-26 with a primary completion date of 2028-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.
Eligibility Criteria
Inclusion Criteria: * new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma will be eligible for enrollment in the study * 18 Years and older Exclusion Criteria: * Under 18 years old * prisoners * those unable to provide informed consent * pregnant women * and those undergoing emergent or urgent operative intervention at the time of diagnosis
Contact & Investigator
Ana Gleisner, MD
PRINCIPAL INVESTIGATOR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT05517811 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Liver Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05517811 currently recruiting?
Yes, NCT05517811 is actively recruiting participants. Contact the research team at tracey.macdermott@cuanschutz.edu for enrollment information.
Where is the NCT05517811 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT05517811 clinical trial?
NCT05517811 is sponsored by University of Colorado, Denver. The principal investigator is Ana Gleisner, MD at University of Colorado, Denver. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.